Back to top
more

CytomX Therapeutics (CTMX)

(Delayed Data from NSDQ)

$1.45 USD

1.45
359,823

+0.07 (5.07%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $1.45 0.00 (0.00%) 7:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug

by Zacks Equity Research

Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why

by Zacks Equity Research

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.

Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.

MAIA Soars 20% on Interim Results From Lung Cancer Study

by Zacks Equity Research

MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.

Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

by Zacks Equity Research

Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.

Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

by Zacks Equity Research

Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO

by Zacks Equity Research

Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

by Zacks Equity Research

Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why

by Zacks Equity Research

Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

by Zacks Equity Research

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: DaVita, Block, Home Depot in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine

by Zacks Equity Research

Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.

Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.

Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study

by Zacks Equity Research

Though data from a mid-stage study shows that treatment with Aclaris' (ACRS) JAK inhibitor met its primary endpoint, it also displays a greater-than-expected placebo effect.

Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday

by Zacks Equity Research

Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.

Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%

by Zacks Equity Research

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel

by Zacks Equity Research

Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.

Allogene (ALLO) Down 20% on Strategic Changes in Pipeline

by Zacks Equity Research

Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.

Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo

by Zacks Equity Research

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday

by Zacks Equity Research

Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.

MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why

by Zacks Equity Research

MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.

Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal

by Zacks Equity Research

Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.

Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy

by Zacks Equity Research

The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.